Ethyl-carbamic acid 1-(6,7-dimethoxy-phthalazin-1-yl)-piperidin-4-yl ester (Carbazeran)

ID: ALA77131

Chembl Id: CHEMBL77131

Cas Number: 70724-25-3

PubChem CID: 71983

Product Number: C136759

Max Phase: Phase

Molecular Formula: C18H24N4O4

Molecular Weight: 360.41

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Carbazeran | UK-31,557 | UK-31557 | Carbazeran|70724-25-3|1-(6,7-dimethoxyphthalazin-1-yl)piperidin-4-yl ethylcarbamate|UK 31557|UK-31,557|UK-31557|0N4I6K95P2|UK31557|1-(6,7-Dimethoxy-1-phthalazinyl)-4-piperidyl ethylcarbamate|Carbazeranum|Carbamic acid, ethyl-, 1-(6,7-dimethoxy-1-phthalazinyl)-4-piperidinyl ester|Carbazeran [USAN:INN]|Carbazeranum [INN-Latin]|UNII-0N4I6K95P2|CARBAZERAN [INN]|Carbazeran (USAN/INN)|CARBAZERAN [USAN]|CHEMBL77131|SCHEMBL122456|Carbazeran, >=96% (HPLC)|2,4,5-TBUTOXYShow More⌵

Canonical SMILES:  CCNC(=O)OC1CCN(c2nncc3cc(OC)c(OC)cc23)CC1

Standard InChI:  InChI=1S/C18H24N4O4/c1-4-19-18(23)26-13-5-7-22(8-6-13)17-14-10-16(25-3)15(24-2)9-12(14)11-20-21-17/h9-11,13H,4-8H2,1-3H3,(H,19,23)

Standard InChI Key:  QJGVXJYGDBSPSJ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA77131

   CARBAZERAN

2. Alternative Forms:

   

   ALA77131

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 360.41

Molecular Weight (Monoisotopic): 360.1798

AlogP: 2.36

#Rotatable Bonds: 5

Polar Surface Area: 85.81

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 5.82

CX LogP: 1.16

CX LogD: 1.15

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.88

Np Likeness Score: -0.67

References

1. Erhardt PW..  (1987)  In search of the digitalis replacement.,  30  (2): [PMID:3027335] [10.1021/jm00385a001]

2. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

3. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW, Knighton DR, Li J, Liu KK, Liu Z, Marx MA, Walls M, Wells PA, Yin MJ, Zhu J, Zientek M..  (2013)  Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.,  4  (1): [PMID:24900568] [10.1021/ml300309h]

4. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

5. Strelevitz TJ, Orozco CC, Obach RS..  (2012)  Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.,  40  (7): [PMID:22522748] [10.1124/dmd.112.045195]

6. Sharma R, Strelevitz TJ, Gao H, Clark AJ, Schildknegt K, Obach RS, Ripp SL, Spracklin DK, Tremaine LM, Vaz AD..  (2012)  Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.,  40  (3): [PMID:22190693] [10.1124/dmd.111.042770]

7. Sharma R, Strelevitz TJ, Gao H, Clark AJ, Schildknegt K, Obach RS, Ripp SL, Spracklin DK, Tremaine LM, Vaz AD..  (2012)  Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.,  40  (3): [PMID:22190693] [10.1124/dmd.111.042770]

8. Hutzler JM, Yang YS, Albaugh D, Fullenwider CL, Schmenk J, Fisher MB..  (2012)  Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.,  40  (2): [PMID:22031625] [10.1124/dmd.111.042861]

9. Manevski N, King L, Pitt WR, Lecomte F, Toselli F..  (2019)  Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.,  62  (24): [PMID:31385704] [10.1021/acs.jmedchem.9b00875]

10. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]

Source

Source(4):

• Scientific Literature
• USP Dictionary of USAN and International Drug Names
• AstraZeneca Deposited Data
• IMI-CARE SARS-CoV-2 Data